Assay of cyclooxygenase-1 and 2 in human monocytes

被引:38
作者
Demasi, M [1 ]
Caughey, GE [1 ]
James, MJ [1 ]
Cleland, LG [1 ]
机构
[1] Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA 5000, Australia
基金
英国医学研究理事会;
关键词
COX-1; COX-2; aspirin; NSAIDs; monocytes;
D O I
10.1007/s000110050655
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design: There is frequently poor correlation between in vitro methods for calculated cyclooxygenase (COX)-1/COX-2 selectivities of inflammatory agents. Therefore, we have examined the use of a single stimulus in a single cell type containing both COX isoforms, for determining the selectivities of COX-inhibitory agents. Methods: Fresh human monocytes were stimulated with arachidonic acid (AA; 10 muM) for 15 min and prostaglandin E-2 (PGE(2)) and thromboxane B-2 (TXB2) production were used as a measure of COX-1 activity. To measure COX-2 activity, cells were transiently pre-treated with aspirin to irreversibly inhibit constitutive COX-1, treated with lipopolysaccharide (LPS) to induce COX-2 and then stimulated with AA. Results: Eicosanoid production in resting monocytes was predominantly COX-1 derived since it was not inhibited by NS-398 and also, COX-2 was not detectable. In LPS treated monocytes pre-treated transiently with aspirin, neither the level of induced COX-2 nor the activity was affected. Using the mean of the results for PGE(2) and TXB2 inhibition, the COX-1/COX-2 ratios of the IC(5)0 values for aspirin and NS-398 are < 0.1 and > 130, respectively. Conclusions: This study has provided a system for investigating inhibition of COX isotypes without the potentially confounding effects of using different cell types with different stimuli for each isotype as seen in other published systems. Dose responses to aspirin and NS-398 which are COX-1 and COX-2 selective inhibitors respectively, confirmed the utility of this system.
引用
收藏
页码:737 / 743
页数:7
相关论文
共 32 条
[1]   PURIFICATION, CHARACTERIZATION AND SELECTIVE-INHIBITION OF HUMAN PROSTAGLANDIN-G/H SYNTHASE-1 AND SYNTHASE-2 EXPRESSED IN THE BACULOVIRUS SYSTEM [J].
BARNETT, J ;
CHOW, J ;
IVES, D ;
CHIOU, M ;
MACKENZIE, R ;
OSEN, E ;
NGUYEN, B ;
TSING, S ;
BACH, C ;
FREIRE, J ;
CHAN, H ;
SIGAL, E ;
RAMESHA, C .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (01) :130-139
[2]   A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors [J].
Brideau, C ;
Kargman, S ;
Liu, S ;
Dallob, AL ;
Ehrich, EW ;
Rodger, IW ;
Chan, CC .
INFLAMMATION RESEARCH, 1996, 45 (02) :68-74
[3]   Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 [J].
Brooks, P ;
Emery, P ;
Evans, JF ;
Fenner, H ;
Hawkey, CJ ;
Patrono, C ;
Smolen, J ;
Breeveld, F ;
Day, R ;
Dougados, M ;
Ehrich, EW ;
Gijon-Baños, J ;
Kvien, TK ;
Van Rijswijk, MH ;
Warner, T ;
Zeidler, H .
RHEUMATOLOGY, 1999, 38 (08) :779-788
[4]   Induction of cyclooxygenase-2 in the brain by cytokines [J].
Cao, CY ;
Matsumura, K ;
Watanabe, Y .
THERMOREGULATION: TENTH INTERNATIONAL SYMPOSIUM ON THE PHARMACOLOGY OF THERMOREGULATION, 1997, 813 :307-309
[5]  
Caughey GE, 1997, J IMMUNOL, V158, P351
[6]  
Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
[7]   Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina [J].
Cipollone, F ;
Patrignani, P ;
Greco, A ;
Panara, MR ;
Padovano, R ;
Cuccurullo, F ;
Patrono, C ;
Rebuzzi, AG ;
Liuzzo, G ;
Quaranta, G ;
Maseri, A .
CIRCULATION, 1997, 96 (04) :1109-1116
[8]   Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays [J].
Cromlish, WA ;
Kennedy, BP .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (11) :1777-1785
[9]   Cyclooxygenase in biology and disease [J].
Dubois, RN ;
Abramson, SB ;
Crofford, L ;
Gupta, RA ;
Simon, LS ;
Van De Putte, LBA ;
Lipsky, PE .
FASEB JOURNAL, 1998, 12 (12) :1063-1073
[10]  
Fort J, 1999, Am J Orthop (Belle Mead NJ), V28, P13